Xiaopan 4.7.2
![xiaopan 4.7.2 xiaopan 4.7.2](https://images.sftcdn.net/images/t_app-cover-l,f_auto/p/88e74ff6-99ea-11e6-ae34-00163ec9f5fa/3744460209/netsetman-screenshot.jpg)
![xiaopan 4.7.2 xiaopan 4.7.2](https://4.bp.blogspot.com/-GgdEZOKL8g0/UjQJ3N7-lQI/AAAAAAAAVTw/jh4z0X2LMAQ/s1600/Xiaopan++0.4.7.1.jpg)
![xiaopan 4.7.2 xiaopan 4.7.2](https://www.researchgate.net/profile/David-Merritt-3/publication/319880273/figure/fig4/AS:941059236454402@1601377414670/15GHz-contour-image-of-Mrk-533-from-the-EVLA-in-the-A-array-configuration-showing-the-C_Q320.jpg)
Takeda analyzed the data, and with all authors jointly interpreted the results.Īuthor names in bold designate shared co-first authorship.Abstract: Background: Positron emission tomography (PET) is the most sensitive and quantitative functional and molecular imaging technique.
#Xiaopan 4.7.2 trial
Personnel from the study sponsor designed the trial in conjunction with the principal investigators. Séverine Vermeire: Financial support for research: MSD, AbbVie, Takeda, Pfizer, Johnson & Johnson Lecture fees: MSD, AbbVie, Takeda, Ferring, Centocor, Hospira, Pfizer, Johnson & Johnson, Genentech/Roche Consultancy: MSD, AbbVie, Takeda, Ferring, Centocor, Hospira, Pfizer, Johnson & Johnson, Genentech/Roche, Celgene, Mundipharma, Celltrion, SecondGenome, Prometheus, Gilead, Galapagos, ProDigest.įundingThis study was sponsored by Takeda. Geert D’Haens: Lecture fees: AbbVie, Biogen, Ferring, Johnson & Johnson, Merck Sharp Dohme, Mundipharma, Norgine, Pfizer, Samsung Bioepis, Shire, Millennium/Takeda, Tillotts and Vifor Consultancy: AbbVie, Ablynx, Allergan, Amakem, Amgen, AM Pharma, Arena Pharmaceuticals, AstraZeneca, Avaxia, Biogen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene/Receptos, Celltrion, Cosmo, Covidien/Medtronics, Echo Pharmaceuticals, Eli Lilly, Engene, Ferring, DrFALK Pharma, Galapagos, Genentech/Roche, Gilead, GlaxoSmithKline, Gossamerbio, Hospira/Pfizer, Immunic, Johnson & Johnson, Lycera, Medimetrics, Millennium/Takeda, Mitsubishi Pharma, Merck Sharp Dohme, Mundipharma, Nextbiotics, Novo Nordisk, Otsuka, Pfizer/Hospira, Photopill, Prometheus Laboratories/Nestle, Progenity, Protagonist, Robarts Clinical Trials, Salix, Samsung Bioepis, Sandoz, Seres/Nestle, Setpoint, Shire, Teva, Tigenix, Tillotts, Topivert, Versant and Vifor. Xiaopan Yao: Employee of Takeda at the time the study was conducted. Lecture fees: Mitsubishi Tanabe Pharma, Pfizer, Eisai, Kyorin Pharmaceutical, AbbVie, Janssen, JIMRO, Ajinomoto Pharma, EA Pharma, Astellas Pharma, Mochida Pharmaceutical, Asahi Kasei Medical, Takeda, Gilead Sciences, Celltrion, Nippon Kayaku, Alfresa Pharma Consultancy: Janssen, Pfizer, Kyorin Pharmaceutical, Mochida Pharmaceutical, Takeda, Eli Lilly, Ferring Pharmaceutical, Nippon Kayaku, Thermo Fisher Scientific, Covidien Japan. Taku Kobayashi: Financial support for research: EA Pharma, Thermo Fisher Scientific, Alfresa Pharma, and Nippon Kayaku. Željko Krznarić: Lecture fees: AbbVie, Hospira, Johnson & Johnson, MSD, Oktal Pharma. Silvio Danese: Lecture fees: AbbVie, Ferring, Hospira, Johnson & Johnson, Merck, MSD, Takeda, Mundipharma, Pfizer Inc, Tigenix, UCB Pharma, Vifor, Biogen, Celgene, Allergan, Celltrion, Sandoz, Boehringer Ingelheim Consultancy: AbbVie, Ferring, Hospira, Johnson & Johnson, Merck, MSD, Takeda, Mundipharma, Pfizer Inc, Tigenix, UCB Pharma, Vifor, Biogen, Celgene, Allergan, Celltrion, Sandoz, Boehringer Ingelheim. Filip Baert: Financial support for research: AbbVie, Chiesi, Ipsen, MSD, Roche Consultancy: AbbVie, Celgene, Falk, Ferring, Janssen, Mundipharma, MSD, Pfizer, Takeda, Vifor. Spouse: Opthotech–consultant, stock options Progenity–consultant, stock Oppilan Pharma–employee, stock options Escalier Biosciences–employee, stock options Precision IBD–employee, stock options Ventyx Biosciences–employee, stock options Vimalan Biosciences–employee, stock options.
#Xiaopan 4.7.2 series
Sandborn: Financial support for research: Atlantic Healthcare Limited, Amgen, Genentech, Gilead Sciences, AbbVie, Janssen, Takeda, Lilly, Celgene/Receptos, Pfizer, Prometheus Laboratories Consulting fees: Abbvie, Allergan, Amgen, Arena Pharmaceuticals, Avexegen Therapeutics, BeiGene, Boehringer Ingelheim, Celgene, Celltrion, Conatus, Cosmo, Escalier Biosciences, Ferring, Forbion, Genentech, Gilead Sciences, Gossamer Bio, Incyte, Janssen, Kyowa Kirin Pharmaceutical Research, Landos Biopharma, Lilly, Oppilan Pharma, Otsuka, Pfizer, Precision IBD, Progenity, Prometheus Laboratories, Reistone, Ritter Pharmaceuticals, Robarts Clinical Trials (owned by Health Academic Research Trust, HART), Series Therapeutics, Shire, Sienna Biopharmaceuticals, Sigmoid Biotechnologies, Sterna Biologicals, Sublimity Therapeutics, Takeda, Theravance Biopharma, Tigenix, Tillotts Pharma, UCB Pharma, Ventyx Biosciences, Vimalan Biosciences, Vivelix Pharmaceuticals Stock or stock options: BeiGene, Escalier Biosciences, Gossamer Bio, Oppilan Pharma, Precision IBD, Progenity, Ritter Pharmaceuticals, Ventyx Biosciences, Vimalan Biosciences. Conflicts of interestThe authors disclose the following: William J.